- Conditions
- Multiple Sclerosis
- Interventions
- Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 58
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Renal Insufficiency
- Interventions
- Dalfampridine-ER
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Anaheim, California • South Miami, Florida
- Conditions
- Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
- Interventions
- 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Imatinib, Fampridine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Louis H. Weimer, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4 DAP
- Drug
- Lead sponsor
- David P. Richman, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Vern C. Juel, M.D.
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR b.i.d. (Twice Daily)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
- Conditions
- Post-ischemic Stroke
- Interventions
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
- Conditions
- Vestibular Migraine, Migraine Disorders, Vestibular Diseases
- Interventions
- 4-aminopyridine, Atenolol, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Burns, Second Degree Burn, Wounds and Injuries
- Interventions
- Drug: 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Nerve Injury, Prostate Cancer
- Interventions
- 4-Aminopyridine, Placebo
- Drug · Other
- Lead sponsor
- John Elfar
- Other
- Eligibility
- 45 Years to 75 Years · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Rochester, New York
- Conditions
- Multiple Sclerosis
- Interventions
- fampridine, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
- Conditions
- Spinal Cord Injury
- Interventions
- Dalfampridine, Placebo
- Drug
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Vocal Weakness(Post-BOTOX Injection)
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cerebral Palsy (CP)
- Interventions
- dalfampridine-ER 10mg, Placebo
- Drug · Other
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Downey, California • Los Angeles, California + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy
- Drug · Behavioral · Other
- Lead sponsor
- MGH Institute of Health Professions
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts